<DOC>
	<DOCNO>NCT01008566</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cixutumumab give together sorafenib tosylate treat patient advanced liver cancer . Monoclonal antibody , cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth . Giving cixutumumab together sorafenib tosylate may kill tumor cell .</brief_summary>
	<brief_title>Cixutumumab Sorafenib Tosylate Treating Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish maximum tolerate dose ( MTD ) IMC-A12 give conjunction standard dose sorafenib patient advance hepatocellular carcinoma ( HCC ) . II . To describe toxicity tolerance IMC-A12 dose study combination standard-dose sorafenib patient advance HCC . III . To evaluate impact IMC-A12 biomarkers relate IGF-1R/IGF pathway think relevant HCC progression drug resistance . IV . To obtain preliminary assessment efficacy description progression-free survival ( PFS ) objective response rate ( RR ) . OUTLINE : This multicenter , dose-escalation study cixutumumab follow extended accrual phase patient treat maximum-tolerated dose . Patients receive cixutumumab IV 1 hour day 1 , 8 , 15 , 22 oral sorafenib tosylate twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Unresectable metastatic HCC standard curative measure exist ; diagnosis hepatocellular carcinoma base least one following : The presence one liver lesion , measure â‰¥ 2 cm , characteristic arterial enhancement venous washout set liver cirrhosis and/or hepatitis B C infection The presence liver lesion ( ) AFP &gt; = 400 Tissue confirmation absence and/or b Tissue availability desire sought , tissue availability mandate accrual study No prior systemic therapy HCC ; patient may prior embolization , chemoembolization , intraarterial chemotherapy infusion , ethanol injection , radiofrequency ablation cryosurgery ECOG 0 1 Life expectancy great 3 month Absolute neutrophil count &gt; 1,000/mm^3 Platelets &gt; 65,000/mm^3 Total bilirubin = &lt; 2 x institutional upper normal limit AST ALT = &lt; 5 x institutional upper normal limit Renal function = &lt; 1.5 mg/dl calculate creatinine clearance &gt; 50 mL/min ( CockcroftGault formula ) PT &lt; 4 second prolongation upper normal limit No evidence encephalopathy last 6 month Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willing sign write informed consent document Local therapy HCC within 4 week prior treatment study recover adverse event related therapy administer 4 week earlier Receiving investigational agent Brain metastasis , poor prognosis , proclivity progressive neurologic dysfunction would confound evaluation neurologic adverse event , potential increase risk CNS adverse event Uncontrolled intercurrent illness include , limited ongoing active infection , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated clinical trial HIVpositive patient ineligible Fasting blood glucose &gt; 160 mg/dL Esophageal gastric variceal bleeding within last 6 Clinically evident ascites ( minimal , medically control ascites detectable image study allow ) ChildPugh C cirrhosis ChildPugh B cirrhosis 7 point Patients unable swallow sorafenib tablet whole ineligible ; ( tablet crush broken ) Cardiac : symptomatic congestive heart failure , unstable angina , clinically significant uncontrolled cardiac dysrhythmia , uncontrolled hypertension ( systolic BP &gt; 150 diastolic BP &gt; 100 two occasion within two week begin therapy protocol , myocardial infarction within 6 month , NYHA class &gt; II , LVEF &lt; normal assess MUGA Fibrolamellar carcinoma mixed variant HCC fibrolamellar histology Hypersensitivity human IgG unless patient subsequently tolerate IgG agent Patients active hepatitis B infection adequate antiviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>